硝苯地平控释片联合缬沙坦治疗对2型糖尿病肾病合并高血压患者血清学指标的影响(1)
[摘要] 目的 探究硝苯地平控釋片联合缬沙坦治疗对2型糖尿病肾病合并高血压患者血清学指标的影响。方法 择2016年10月—2019年10月内该院76例2型糖尿病肾病合并高血压患者为对象。基于自主原则成立参照及实验两组。参照组予硝苯地平控释片，实验组予硝苯地平控释片与缬沙坦，对比两组血清学指标。结果 实验组CysC、Hcy、mALB、血压指标水平(0.54±0.08)mg/L、(6.65±0.77)μmol/L、(26.11±2.63)mg/L、(79.25±5.57)mmHg、(125.49±5.38)mmHg及HbA1c、SCr、BUN、空腹血糖水平及餐后2 h血糖水平(5.04±0.61)%、(60.32±4.78)μmol/L、(5.19±0.11)mmHg、(5.54±0.62)mmHg、(7.37±1.26)mmHg相较于参照组(1.21±0.04)mg/L、(10.24±1.36)μmol/L、(55.37±3.48)mg/L、(90.32±6.37)mmHg、(136.27±6.45)mmHg、(7.31±0.81)%、(68.23±5.12)μmol/L、(6.45±0.17)mmHg、(9.01±0.78)mmHg、(14.17±2.61)mmHg均呈现显著优越性，差异有统计学意义(t=25.385、28.721、68.525、12.246、12.348、17.571、15.036、22.147、17.158、22.208，P<0.05)。结论 2型糖尿病肾病合并高血压患者应用硝苯地平控释片联合缬沙坦治疗疗效显著，能有效改善患者血清学指标。
[关键词] 2型糖尿病肾病;高血压;硝苯地平控释片;缬沙坦
[中图分类号] R578.2 [文献标识码] A [文章编号] 1672-4062(2020)11(a)-0064-03
[Abstract] Objective To investigate the effect of nifedipine controlled-release tablets combined with valsartan treatment on serological parameters in patients with type 2 diabetic nephropathy complicated by hypertension. Methods A total of 76 patients with type 2 diabetic nephropathy and hypertension in the hospital from October 2016 to October 2019 were selected as subjects. Two groups of reference and experiment were established based on the principle of autonomy. The reference group was given nifedipine controlled release tablets， and the experimental group was given nifedipine controlled release tablets and valsartan， and the serological indicators of the two groups were compared. Results Experimental group CysC， Hcy， mALB， blood pressure index level (0.54±0.08)mg/L， (6.65±0.77)μmol/L， (26.11±2.63)mg/L， (79.25±5.57)mmHg， (125.49±5.38)mmHg and HbA1c， SCr， BUN， fasting blood glucose level and 2 h postprandial blood glucose level (5.04±0.61)%， (60.32±4.78)μmol/L， (5.19±0.11)mmHg， (5.54±0.62)mmHg， (7.37±1.26)mmHg compared to the reference group (1.21±0.04)mg/L， (10.24±1.36)μmol/L， (55.37±3.48)mg/L， (90.32±6.37)mmHg， (136.27±6.45)mmHg， (7.31±0.81)%， (68.23±5.12)μmol/L， (6.45±0.17)mmHg， (9.01±0.78)mmHg， (14.17±2.61)mmHg all showed significant superiority， and the difference was statistically significant(t=25.385， 28.721， 68.525， 12.246， 12.348， 17.571， 15.036， 22.147， 17.158， 22.208， P<0.05). Conclusion Nifedipine controlled-release tablets combined with valsartan are effective in patients with type 2 diabetic nephropathy and hypertension and can effectively improve the serological parameters of patients., 百拇医药(陆伟伟)
[关键词] 2型糖尿病肾病;高血压;硝苯地平控释片;缬沙坦
[中图分类号] R578.2 [文献标识码] A [文章编号] 1672-4062(2020)11(a)-0064-03
[Abstract] Objective To investigate the effect of nifedipine controlled-release tablets combined with valsartan treatment on serological parameters in patients with type 2 diabetic nephropathy complicated by hypertension. Methods A total of 76 patients with type 2 diabetic nephropathy and hypertension in the hospital from October 2016 to October 2019 were selected as subjects. Two groups of reference and experiment were established based on the principle of autonomy. The reference group was given nifedipine controlled release tablets， and the experimental group was given nifedipine controlled release tablets and valsartan， and the serological indicators of the two groups were compared. Results Experimental group CysC， Hcy， mALB， blood pressure index level (0.54±0.08)mg/L， (6.65±0.77)μmol/L， (26.11±2.63)mg/L， (79.25±5.57)mmHg， (125.49±5.38)mmHg and HbA1c， SCr， BUN， fasting blood glucose level and 2 h postprandial blood glucose level (5.04±0.61)%， (60.32±4.78)μmol/L， (5.19±0.11)mmHg， (5.54±0.62)mmHg， (7.37±1.26)mmHg compared to the reference group (1.21±0.04)mg/L， (10.24±1.36)μmol/L， (55.37±3.48)mg/L， (90.32±6.37)mmHg， (136.27±6.45)mmHg， (7.31±0.81)%， (68.23±5.12)μmol/L， (6.45±0.17)mmHg， (9.01±0.78)mmHg， (14.17±2.61)mmHg all showed significant superiority， and the difference was statistically significant(t=25.385， 28.721， 68.525， 12.246， 12.348， 17.571， 15.036， 22.147， 17.158， 22.208， P<0.05). Conclusion Nifedipine controlled-release tablets combined with valsartan are effective in patients with type 2 diabetic nephropathy and hypertension and can effectively improve the serological parameters of patients., 百拇医药(陆伟伟)